TITLE. COVID-19 in Spain: age, Interleukin-6, C Reactive Protein and lymphocytes as key clues from a multicenter retrospective study.

AUTHORS.

Aurora Jurado[1,2], María C. Martín[1,3], Cristina Abad-Molina[4], Antonio Orduña[4], Alba Martínez[5], Esther Ocaña[5], Oscar Yarce[2], Ana M. Navas[2] , Antonio Trujillo[2], Luis Fernández[6], Esther Vergara[6] , Beatriz Rodríguez[7], Bibiana Quirant[8], Eva Martínez[8], Manuel Hernández[9], Janire Perurena-Prieto[9], Juana Gil[10], Sergi Cantenys[10], Gema González-Martínez[11], María T. Martínez-Saavedra[11], Ricardo Rojo[12], Francisco M. Marco[13], Sergio Mora[13] Jesús Ontañón[14], Marcos López-Hoyos[15], Gonzalo Ocejo-Vinyals[15],Josefa Melero[16], Marta Aguilar[16], Delia Almeida[17], Silvia Medina[17], María C. Vegas[18], Yesenia Jiménez[18], Álvaro Prada[19], David Monzón[19], Francisco Boix[20], Vanesa Cunill[21], Juan Molina[2]

[1]These authors contributed equally to this manuscript.

Affiliations.

[2]Department of Immunology.and alergology. Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.

[3]Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain

[4]Department of Microbiology and Immunology. Hospital Clínico Universitario, Valladolid, Spain

[5]Laboratory Unit. Complejo Hospitalario, Jaén, Spain

[6]Laboratoy of Immunology and Genetics. Hospital San Pedro de Alcántara, Cáceres, Spain

[7]Laboratory Unit. Hospital Juan Ramón Jiménez, Huelva, Spain

[8]Department of Immunology. Hospital Germans Trias i Pujols, Barcelona, Spain

[9]Department of Immunology. Hospital Universitario Vall d'Hebron, Barcelona, Spain

[10]Department of Immunology. Hospital general Universitario and Instituto de investigación sanitaria "Gregorio Marañón", Madrid, Spain

[11]Unit of Immunology. Hospital Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain

[12] Department of Immunology. Complejo Hospitalario, La Coruña, Spain

[13]Laboratory Unit. Hospital General, Alicante, Spain

[14]Laboratory Unit. Hospital General Universitario, Albacete, Spain

[15]Hospital Universitario Marqués de Valdecilla, Santander, Spain

[16]Hospital Infanta Cristina, Badajoz, Spain

[17]Laboratory Unit. Complejo Hospitalario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain

[18]Department of Immunology. Fundación Jiménez Díaz, Madrid, Spain.

[19] Department of Immunology. Hospital de Donostia, San Sebastián, Spain.

[20]Department of Immunology. Hospital Clínico Universitario, Salamanca, Spain.

[21]Department of Immunology. Hospital Universitario Son Espases, Palma de Mallorca, Spain .

Keywords: severe acute respiratory syndrome coronavirus 2, immunosenescence, lymphocytes, interleukin-6, Spain, immunology, renin-angiotensin system, ACE2, C- reactive protein.

Running Title: COVID-19: age, Interleukin 6 and lymphocytes

Author for correspondence: Dra M Carmen Martín Alonso. Centro de Hemoterapia y Hemodonación de Castilla y León. Paseo de Filipinos s/n. 47007 Valladolid (Spain); email: cmartinalo@saludcastillayleon.es. Tf.: +34 983 41 88 23 ext 89673 Mobile +34 686 24 73 31

Alternate author for correspondence: Dra. A Jurado Roger. Department of Immunology and Allergollogy. Hospital Universitario Reina Sofía. Avd. Menéndez Pidal s/n. 14904 Córdoba (Spain); email: aurora.jurado.sspa@juntadeandalucia.es. Tf: +34670945703.

Article Summary main points: Age arises as a crucial factor for COVID-19 severity in our series. It is as well one of the major determinants for all other COVID19 risk comorbidities, such as hypertension, diabetes or dyslipidemia. Immunosenescence would be therefore under immune overload.

ABSTRACT

Background. SARS-CoV-2 infection has widely spread to the hugest public health challenge to date, COVID-19 pandemic. Different fatality rates among countries are probably due to unstandardized records being carried out by local health authorities. Spanish case-fatality rate is 11.86%, far higher to those reported in Asia or by other European countries.

Methods. A multicenter retrospective study of demographic, clinical, laboratory and immunological features of 574 Spanish COVID-19 inpatients (59.4% males) and their outcomes was performed.

Results. 27.7% cases presented a mild curse, 42% a moderate one and 30.3%, severe. Ages ranged from 18 to 98 (average 63.2). Interleukin 6 was higher as increasing severity. On the other hand, CD8 lymphocyte count was significantly lower as severity grew and subpopulations CD4, CD8, CD19 and NK showed concordant lowering trends. Severity-related natural killer percent descents were evidenced just within aged cases. A significant severity-related decrease of CD4 lymphocytes was found in males. The use of renin-angiotensin system blockers was associated with moderate or mild disease courses.

Conclusions. Clinical course of the disease is more severe in this study than in previous literature cohorts. Age and age-related comorbidities, such as dyslipidemia, hypertension or diabetes, were also higher. Immunosenescence might be therefore a suitable explanation for immune system effectors severity-related hampering. Adaptive immunity would go exhausted and a huge ineffective and almost deleterious innate response would account for COVID-19 severity. Hypertensive patients treated with renin-angiotensin system blockers developed milder forms of the disease.

Abbreviations.

Angiotensin-converting enzyme 2 (ACE2); renin-angiotensin system blockers (RASB); lactate dehydrogenase (LDH); C- reactive protein (CRP); interleukin-6 (IL-6); immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M (IgM); polimerase chain reaction (PCR); standard deviation (SD); interquartile range (IQR); Natural Killers (NK).

INTRODUCTION

SARS-CoV-2 infection has become worldwide widespread. Never before did we experience a health emergency like this. At the time of writing, four months after the first diagnosed case [1] the virus has infected 4 122 173 people, with an overall case-fatality rate of 6.86% [2] far exceeding the 1% reported outside the epicenter by early studies [3]. It can be traced back to the end of February, when the pandemic started to rapidly expand, hitting the hardest some European countries, such as Spain, with case-fatality rates around 11.86%. So far, we lack an explanation to this particular behavior, although it could be due to different local approaches for records and statistics of infected patients within countries. Absolute mortality rates are far higher in Spain than those reported in Asia or other European countries [4].

It was by 2002, in the SARS-CoV epidemic, when a coronavirus was for the first time revealed to be highly pathogenic. Coronaviruses were until then considered to cause only mild infections, mainly in immunocompromised people [5]. Compared with SARS-CoV, SARS-CoV-2 has shown a much higher infectivity with a doubling time of 2.3-3.3 days, and a basic reproductive number $[R_0]$ of 5.7 [6]. SARS-CoV-2 can be considered specially challenging due to several intrinsic and extrinsic characteristics. It has highly variable prevalence and outcomes within countries depending on age, weather and social habits.

Angiotensin-converting enzyme 2 (ACE2) is the receptor for SARS-CoV-2 and plays a cardinal function in human infection [7]. ACE2 has two isoforms; a large one anchored to the cell membrane [8] and a small soluble isoform that lacks anchorage to the membrane and circulates in low amounts in blood [9]. Hence, it has been suggested that the use of drugs that increase the expression of ACE2, such as angiotensin converting enzyme inhibitors and angiotensin II receptor blockers could enhance infection [10] and on the other hand, increasing soluble ACE2 may be a therapeutic tool to block the virus [11]. The habit of smoking can as well rise ACE2 expression and might be therefore a risk factor for SARS CoV2 infection [12].

Both innate and adaptive responses are involved in SARS-CoV-2 fighting [13]. An accurate immune response is essential for infection resolution. In SARS-CoV-2 infection, an aberrant immune response itself might be the key to understand the immunopathogenesis. It looks as if the progression to severe COVID-19 were associated with a poor

adaptive immune response [14] and with an exacerbation of the innate immune response, with an increase in plasma levels of cytokines and pro-inflammatory chemokynes [15].

Understanding the pathogenesis of the virus as well as identifying risk or severity factors for COVID-19, are key points for identifying disease evolution biomarkers and taking immediate preventive measures.

The aim of this study was therefore to obtain, within the shortest possible time, a reliable snapshot of the demographic and clinical characteristics of COVID-19 patients admitted to Spanish hospitals along the first month of the pandemic and to reveal risk factors regarding outcome severity. This knowledge would help manage both clinical and health decisions.

METHODS

Study design and participants

A retrospective multicenter analysis was performed on the first consecutive set of SARS-CoV-2 infected inpatients, microbiological confirmed by positive PCR test, during the second half of March, 2020. Cases were tracked for a three-week follow-up period from admission to discharge. A minimum sample size of 20 patients was considered for every hospital. In some cases, this minimum was exceeded. A total of 642 medical records of individuals over 18 years old, from 19 Spanish hospitals were initially reviewed. After data quality assessment, 574 patients were finally included in the analyses. Participants were stratified before data analyses into three severity groups according to the following clinical criteria:

- Mild: individuals whose clinical symptoms were mild with no abnormal radiological findings.

- Moderate: cases with confirmed pneumonia that was not considered severe

- Severe: when at least one of the following criteria was met: acute respiratory distress, shock, admission to the intensive care unit (ICU), or the process was so considered by the physician in charge. Any "exitus" was as well classified as severe.

Age was recoded into 5 groups to ease analysis: <30, 30-45, 45-60, 60-75, >75

This retrospective observational study was conducted according with national regulations, institutional policies and in the tenets of the Helsinki Declaration. It was approved by the local institutional Ethics Committee of any involved hospitals.

Data collection

All data were extracted from electronic medical records. The collection form included demographic, epidemiological and clinical data: age, sex, history of diabetes mellitus (DM), dyslipidemia, hypertension (HTA), RASB intake, COVID-19 severity, time from onset to diagnosis, laboratory data on admission and discharge, treatment, and outcome. At the end of data collection, some patients were still in hospital. In these cases, laboratory data at discharge could not be provided.

Laboratory data

Major laboratory markers were extracted from medical records at admission and discharge. Routine blood examinations included leukocyte, neutrophil and lymphocyte count (cells*10^3/µL) and lymphocyte percentage. Serum biochemical tests recorded were ferritin (µg/L), lactate dehydrogenase (LDH, U/L), C- reactive protein (CRP) and D-dimer (µg/L). Immunological tests recorded were interleukin-6 (IL-6, pg/mL), Lymphocyte population count (cells*10^3/µL) and percentage by flow cytometry, immunoglobulins IgG, IgA and IgM (mg/dL).

Statistical analysis

Demographic and clinical characteristics of patients were expressed as their mean and standard deviation (SD); when not adjusting to a normal distribution, median was used to represent non parametrical data for continuous variables and frequency distributions are reported for categorical variables.

Kolmogorov-Smirnov test was performed on each continuous variable to contrast normality. To analyze the overall differences between the three groups: mild, moderate, and severe type, ANOVA was tested on variables with normal distribution and $n > 30$ (age, % and CD4 lymphocyte count, % of CD8 lymphocytes, % of CD19 lymphocytes and % of NK). To analyze severity relationships of non-parametric or $n < 30$ variables, a Kruskal-Wallis test was used. A t-test was performed to contrast damage-free discharge for normal variables and a Mann Whitney test for non-parametric measures. To contrast the Ho of independence within categorical variables, Pearsons' Chi-square and Fisher's exact test were used. To compare values of recurrent parameters measured in a same individual at admission and discharge, Wilcoxon test for paired data was performed.

RESULTS

A total of 574 SARS-CoV-2 infected inpatients from 19 Spanish Hospitals were included. Twenty-seven percent (27.7%) of cases presented a mild curse, 42.0% a moderate one and 30.3% a severe one. By data collection deadline, 266 patients had been discharged and 84 had died. Descriptive baseline characteristics of population (valid n, frequencies, percentages, mean, median, standard deviation and interquartile range) are shown in Table 1. Categorical variables stratified by severity are shown in Table 2.

Fifty nine percent (59.4%) of cases were male. Ages in our cohort ranged from 18 to 98 years, with a mean of 63.2 years (SD 16.4). Concerning comorbidities, 52.4% were hypertensive, 63.2% of them were treated with blockers of renin-angiotensin system (RABs). Twenty-eight percent 28.9% had dyslipidemia and 23.8% suffered diabetes. Immunodeficiencies were most often secondary to other processes, such as a transplantation or chemotherapy treatment, this cases accounted for 8.2% (n=39) as seen in Table 1.

Both moderate and severe courses were found to be significantly associated with older age (p= 0.014), male gender (p<0.001), dyslipidemia (p=0.006), hypertension (p=0.04) and diabetes (p=0.007). Severe cases over the age of 75 accounted for a 36.1%. The use of renin-angiotensin system blockers by hypertensive patients was associated, (p=0.031), with mild or moderate outcomes (Table 2).

Once at hospital, 84.8% of inpatients received antibiotics; the most commonly prescribed ones were azithromycin combinations (71.3%); those treated with antimalarials accounted for 72.6% and 66% received antivirals, being litonavir/ritonavir the most widely used. Around one half, 51% of cases, received combined therapy with antibiotics, antimalarials and antivirals (commonly named triple therapy). Immunosuppressant drugs were used in 18.7% cases. Anti-cytokine therapy was used in 8.6%, mostly anti-IL-6R (Tocilizumab), and 17.7% were treated with interferons α or β (Table 1).

On admission, means of laboratory parameters, IL-6, CRP, ferritin, D-dimer, LDH, leukocyte and neutrophil counts, were above reference ranges, opposite to lymphocyte subsets' counts (Table 1). Higher severity was significantly associated with higher IL-6, CRP, ferritin, D-dimer, LDH, leukocyte and neutrophil counts, but lower lymphocyte percent (Supplementary Table 1).Mean values of lymphocyte subpopulations percentages (n=54) were within normality ranges. CD8 Lymphocyte count was found to be significantly higher in mild cases, a similar trend was

found for CD4, CD8, CD19 and NK percentages. IgG and IgM values were as well inversely related to severity (Supplementary Table 1).

At discharge, IL-6, ferritin, D-dimer, LDH, leukocyte and neutrophil counts remained significantly higher within severe cases as compared to mild or moderate ones. Lymphocyte count turned significantly higher in severe cases as compared to mild or moderate (Supplementary Table 1). CRP values at discharge were nearly in range regardless of severity. Notwithstanding, when comparing laboratory data at discharge with those on admission, an overall return to reference ranges of most parameters was observed, with lower mean values of CRP, LDH and IL-6 and higher mean values of percentage and absolute lymphocyte count. D-dimer and ferritin, still showed values above reference ranges with no significant differences as compared to these upon arrival.

Most differences among groups are kept as regarding aging (Figure 1). It could be evidenced that lymphopenia and increased IL-6 remained significant regarding severity in all age groups but in patients under 30. CD8 population differences [both for absolute count and percent] were significant only as regarding 45-60 group (the largest one). Lymphocyte count decrease –that was seen as a global change- was only evidenced for 30-45 and 45-60 age ranges. NK % was higher in milder cases within older individuals (60-75 and <75). Severity-related decreases of CD4 (p 0.007) and CD8 (p 0.008) lymphocytes were evidenced just in males (Figure 2). Hypertension, dyslipidemia and diabetes grew more frequent with age (p<0.001, Table 3). These four risk factors showed strong interference (Figure 3). Nevertheless, a predictive model couldn't be proposed due to frequent missing values.

DISCUSSION

COVID-19 pandemic has become particularly virulent in Mediterranean countries such as Spain, both in terms of number of affected people and fatalities. This is the first report on Spanish COVID-19 inpatients; our aim is to outline disease's demographic characteristics, risk factors and laboratory parameters, in relationship to disease severity.

In our series, 27.7% of patients showed a mild course, 42% a moderate course and 30.3% a severe one. Several works analyze severity in COVID-19 inpatients, almost all from Chinese hospitals. Those, including two multicenter studies, show a presentation in which the most severe cases ranged from 16% to 26% [16-19], except for the study of Zhou et al. [20], where critical cases reached 28%.

It has been reported by other authors in papers on risk factors affecting the course of the disease, that older patients or those with at least one previous comorbidity have a worse prognosis [16,19-21]. There are, however, remarkable differences within these studies, mostly reporting data from Chinese patient cohorts. Spanish inpatients age was much

higher than previously reported ones, with an average of 63.2 years. Previous literature, including one meta-analysis and two multicenter studies, report ages ranging from 36 to 58 [16-20,22-24]. On the other hand, Grasselli et al. [25], in a multicenter Italian study focusing on patients admitted to the ICU, reports an average age of 63, similar to that in our cohort.

In SARS-CoV-2 infection, the number of pediatric patients is lower with milder symptoms and better prognosis [26] as compared to adults. This fact highlights the possible effect of immunosenescence on the course of the disease [27]. Immunosenescence refers to the age-associated decline of the immune system, affecting both innate and adaptive immunity. Aging is associated with a greater susceptibility to infections [28]. People over 60 represent 11% of the worldwide population and they are expected to reach 22% by 2050 [28]. In Spain, to date, 19.4% of the population is over 65 [29].

Possibly due to ageing, it can be observed that frequencies for comorbidities such as hypertension or diabetes, were higher in our series than those reported in previous studies [16,17, 19-24,30] and higher too than the diabetes prevalence among Spanish adult population (23.5% vs 13.8%) [31]. Notwithstanding, the prevalence of hypertension mirrored those of the general adult Spanish population (overall, 42.6%; people over 60, 75.4%) [32]. Not only SARSCoV2, but most human coronaviruses strike harder the elderly and those with underlying comorbidities [33], probably as a consequence of a worse immune response control.

As in previous studies, patients were mostly males [19, 20, 22, 24]. This fact is even more noteworthy, considering that the percentage of men in the Spanish population over 50 years of age is 41.7% [29], under 59.4% in our COVID-19 cohort. In addition to remark, male gender was associated with severity. There is Italian report of patients admitted to ICU, holds a percentage of males reaching 80% [25] that would go in the same line of our observed gender effect on severity.

Concerning laboratory parameters, our findings were comparable to those reported in previous studies, with increases of acute phase reactants (CRP, D-dimer, LDH, ferritin) growing with severity and decreasing when the evolution of patients was favorable [19, 20, 22, 30]. Particularly striking was the evolution of the CRP, which was almost within reference range at discharge.

Several publications have focused on immunological markers in COVID-19 [19, 20, 30]. The most extensive one is the work of Diao et al. [14], which analyzes the secretory profile of inflammatory cytokines, lymphocyte populations and their relationship to disease severity in 499 patients. The authors found an increase in pro-inflammatory cytokines

inversely correlated to T-lymphocyte populations. This immune profile is as well related to the severity of the disease. CD4, CD8 and IL-6 are reported to covariate at least in mild cases [34] and behave like our series, where an increase in IL-6 and a decrease in both total lymphocytes and lymphocyte populations could be seen. Once again, these changes were greater, the more severe the condition. However, in our study almost all lymphocyte populations CD4, CD8, CD19 and NK were below reference ranges upon arrival and were even more markedly decreased in severe cases, in spite of differences being only significant for CD8 population as regarding overall data.

Since the seminal publication of Lei Fang et al. on the possible involvement of renin-angiotensin system blockers in SARS-CoV-2 infection [10], less than two months ago, there has been much ado about. No sooner had the scientific community realized its foreseeable impact, they began to take sides with articles both for and against the hypothesis [35-38]. ACE2 molecules are the pathway used by SARS-CoV-2 to enter the cell [39]. RASB indirectly increase the expression and secretion to the extracellular medium of ACE2 in various cell types, including airway alveolar epithelial cells [35]. Therefore, RASB use might enhance both, the entry of the virus or its blockade preventing it from infecting the cell [36]. Additionally, the expression of ACE2 is associated with positive effects on lung homeostasis, those could be beneficial for tissue recovery from the damage caused by SARS-CoV-2 infection [11, 36]. ACE2 expression is reported to be related to age and sex. It would be highest in children and young women, decreasing with ageing, and would be lowered due to chronic disease comorbidities, including diabetes and hypertension. ACE2 will inversely correlate severity and poor outcomes. Most literature for or against the role of the use of RASB consist mainly of theoretical positioning, based on the knowledge of these drugs' physiological actions. There are limited original studies analyzing RASB intake effect on COVID-19. Tedeschi et al. [40], in order to elucidate whether RASB treatment had an impact on COVID-19 mortality, analyze 311 hypertensive patients hospitalized in 10 Italian centers. At multivariate Cox regression analysis of intra-hospital mortality, the use of RASB was not associated with outcome. Moreover, Chen et al. [30] report 113 hypertensive patients, 33 [29.2%] that were on RASB treatment, 87.9% of whom had a moderate course of the disease and 12.2% a severe or critical course. In our series, of the 290 hypertensive patients, 190 [67.4%] were taking RASB; a feature comparable to the intake of these compounds by the Spanish hypertensive population [32]; those patients treated with RASB drugs had a milder course of the disease (OR 0.61, 95% CI [0.37-0.99]; p 0.03).

The present study has two major limitations. The firs one is derived from its retrospective design. As we are reporting on the very first cases of the disease in Spain, several immunological parameters of interest were not systematically

tested. The other constraint is the short follow-up period of patients, which limits the possibility to have a full track of those who were still in hospital by data collection deadline. Consequently, the relationship among other variables such as treatment or other outcomes such as death, have not been here analyzed.

To summarize, our patients are older and developed more often severe COVID-19 condition than the previously reported cohorts. Age has emerged as a crucial factor in our series. Age is as well one of the major determinants for all other COVID-19 risk comorbidities, such as hypertension, diabetes, or dyslipidemia. Immunosenescence might be a suitable explanation for the immune overwhelming observed in the severest cases. Regarding not only our series but other wide world ones, the effectors of the immune system are hampered as severity increases. Adaptive immunity has been suggested to be disabled by SARS CoV2, that feature is so named exhausted immunity. This exhaustion would be coupled with a huge ineffective and almost deleterious innate response.

Further studies specifically aimed at assessing the immune system status in SARS-CoV-2 infected patients should be carried out to support immunosenescence hypothesis. Nevertheless, it is clear from data that elderly are at special COVID-19 risk and should be therefore paid special attention by public health services.

Notes.

Author contributions. AJ and MCM conceived the idea for this study, designed the protocol, analyzed the data and drafted the manuscript. The remaining authors collected the data and assessed for data quality. All authors provided critical revisions and approved the final version of the manuscript.

Funding. This work has been carried out without funding.

Potential conflicts of interest. Authors stated no conflicts of interest.

Acknowledgments

The authors thank to all caregivers who indirectly contributed to this multicenter study. They also thank Sociedad Española de Inmunología (Spanish Society for Immunology) for its support and endorsement

Data sharing statement

Data collected for the study, including fully anonymized participant data, are available to others.

Data available include: fully anonymized participant data and data dictionary. Related documents are available from the date of publications henceforth: study protocol, statistical analysis, and approval of Ethical Board. These documents are available from the date of publications henceforth at email address cmartinalo@saludcastillayleon.es or aurora.jurado.sspa@juntadeandalucia.es

Data will be shared after approval of proposals by the Valladolid Este Ethical Committee

References

1. Du Toit A. Outbreak of a novel coronavirus. *Nat Rev Microbiol,* 2020;18(3):123.

2. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available at: https://coronavirus.jhu.edu/map.html

3. Kenji Mizumoto K, Gerardo Chowell G. Estimating Risk for Death From 2019 Novel Coronavirus Disease, China, January-February 2020. *Emerg Infect Di,s* 2020;26(6). Available at: https:// doi: 10.3201/eid2606.200233.

4. Oksanen A, Kaakinen M, Latikka R, Savolainen I, Savela N, Koivula A. Regulation and trust: 3-month follow-up study on COVID-19 mortality in 25 european countries. *JMIR Public Health Surveill* 2020;6(2]) e19218.

5. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol,* 2019;17(3):181-192 PMID:30531947

6. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. *Emerg Infect Dis,* 2020;26(7). Available at: https://doi.org/10.3201/eid2607.200282

7. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med,* 2020;1-8. Available at: https://doi: 10.1007/s11684-020-0754-0

8. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H. 2020. Genomic Characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet.* 395(10224):565-574.

9. Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K. et al. Targeting and degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. *Hypertension,* 2010;55(1):90-8.

10. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med,* 2020;8(4): e21.

11. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? *Clin Sci [Lond,]* 2020;134(5):543-545.

12. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2. *Am J Respir Crit Care Med,* 2020. Available at: https://doi: 10.1164/rccm.202003-0693LE

13. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. *Cell Death Differ,* 2020;27(5):1451-1454

14. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L et al. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). *medRxiv preprint*, 2020. Available at: https://doi.org/10.1101/2020.02.18.20024364

15. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol,* 2017;39(5):529-539

16. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 [COVID-19] in Changsha. *Eur Rev Med Pharmacol Sci*, 2020;24(6):3404-3410.

17. Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y et al. Clinical characteristics and outcomes of hospitalized patients with COVID-19 treated in Hubei [epicenter] and outside Hubei [non-epicenter]: A Nationwide Analysis of China. *Eur Respir J,* 2020;2000562. Available at: https://www. **DOI:** 10.1183/13993003.00562-2020

18. Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. *J Infect,* 2020;80[4]:401-406.

19. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J. COVID-19 with Different Severity: A Multi-center Study of Clinical Features. *Am J Respir Crit Care Med*, 2020. Available at: https://doi: 10.1164/rccm.202002-0445OC.

20. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*, 2020;28;395(10229):1054-1062.

21. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis*, 2020. Available at: https://doi.org/10.1093/cid/ciaa248

22. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol*, 2020. Available at: https://doi: 10.1002/jmv.25757.

23. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*, 2020;13. Available at: https://doi: 10.1001/jamainternmed.2020.0994

24. Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X. Clinical features and shortterm outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. *Clin Infect Dis*, 2020. Available at https://doi.org/10.1093/cid/ciaa243

25. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA*, 2020;6. Available at https://doi: 10.1001/jama.2020.5394.

26. JCai J, Xu J, Lin D, Yang Z, Xu L, Qu Z et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. *Clin Infect Dis,* 2020;ciaa198. Available at: https://www.doi.org/10.1093/cid/ciaa198

27. Koff WC, Williams MA. Covid-19 and Immunity in Aging Populations. A new research agenda. *N Engl J Med*, 2020. Available at: https://www.DOI: 10.1056/NEJMp2006761

28. Pera A, Campos C, López N, Hassouneh F, Alonso C, Tarazona R, et al. mmunosenescence: implications for response to infection and vaccination in older people. *Maturitas*, 2015;82(1):50-5.

29. Instituto Nacional de Estadística. Ministerio de Economía y Hacienda. Gobierno de España. Available at: https://www.ine.es/jaxi/Tabla.htm?path=/t20/e245/p04/provi/l0/&file=0ccaa003.px&L=0

30. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Inves,* 2019;pii:137244. Available at: https://www.doi: 10.1172/JCI137244.

31. Soriguer F, Valdes S, Rojo G. The Di@bet.es study: and now what? *Av Diabeto,.* 2012;28(2):35-37

32. Menéndez E, Delgado E, Fernández-Vega F, Prieto MA, Bordiú E. Prevalence, diagnosis, treatment, and control of hypertension in Spain. Results of the Di@bet.es Study. *Rev Esp Cardiol,* 2016;69(6)572–578

33. Felsenstein S, Herbert JA, Paul S, McNamara P, Hedrich CM. COVID-19: Immunology and treatment options. *Clin Immunol*, 2020;215:108448. Available at: https://doi.org/10.1016/j.clim.2020.108448

34. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus [COVID-19] infected patients. *Br J Haematol*, 2020;189(3):428-437.

35. Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with COVID-19 infection taking ACEI/ARB. *Curr Cardiol Rep*, 2020;22(5):31.

36. Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus disease 2019 [COVID-19]: Do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? *J Am Heart Assoc*, 2020;9(7):e016509.

37. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System—a Call for Epidemiologic Investigations. *Clin Infect Dis,* 2020;ciaa329. Available at: https://doi: 10.1093/cid/ciaa329.

38. Sommerstein R. 2020. Re: Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. *BMJ*, 2020;368:m81. Available at: https://www.bmj.com/content/368/bmj.m810/rr-2

39. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z et al. Structural and functional Basis of SARS-CoV-2 entry by using human ACE2. *Cell,* 2020;pii:S0092-8674[20]30338-X. Available at: https://doi: 10.1016/j.cell.2020.03.045

40. Tedeschi S, Giannella M, Bartoletti M, Trapani F, Tadolini M, Borghi C, et al. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19. *Clin Infect Dis,* 2020;ciaa492. Available at: https://doi.org/10.1093/cid/ciaa492

TABLES

Table 1. Baseline characteristics of the study population

Clinical and demographic characteristics	All patients n=574; (%)
Severity	
Mild	159 (27.7)
Moderate	241 (42)
Severe	174 (30.3)
Gender	
Male	341 (59.4)
Female	233 (40.6)
Hypertension	290 (52.4)
RASB intake	
no	100 (32.6)
yes	190 (67.4)
Dyslipidemia	157 (28.9)
Diabetes	129 (23.8)
Immunodeficiency (primary or secundary)	39 (8.2)
Antiviral therapy	378 (66.0)
Antimalarial therapy	416 (72.6)
Antibiotic therapy	487 (84.7)
Immunosuppression therapy	106 (18.7)
Anti-cytokine therapy	49 (8.6)
Interferon therapy	101 (17.7)
Triple therapy	293 (51.0)

	Ref.v	n	Mean	Median	SD	IQR
Age		574	63.2	64.0	16.4	52-76

laboratory data on admission

IL6 (pg/mL)	<4.4	253	114.3	41.1	355.8	16.3-94.6
CRP (mg/L)	<10	518	111.80	87.60	93.96	39-154.3
ferritin (ng/mL)	20-250	295	1112.71	793.00	1528.53	361-1417
D-dimer (ng/mL)	<500	455	1888.58	621.00	8222.87	400-1172
LDH[g] (U/L)	120-246	459	334.82	292.00	187.67	232-393
days from onset to admission		538	7.25	7.00	5.15	4-10
Leucocyte count (cells $^{.}10^3$/µL)	4-12.4	562	7.60	6.40	5.62	4.89-9.03
Neutrophil count (cells $^{.}10^3$/µL)	1.9-8	562	5.66	4.62	3.71	3.31-7.12
Lymphocyte count (cells $^{.}10^3$/µL)	0.9-5	562	1.17	1.00	1.07	0.71-1.4
Lymphocyte %	19-48	562	18.28	16.00	11.41	9.7-23.5
CD3+CD4+ %	25-65	54	44.71	44.95	10.74	37-51.3
CD3+CD4+ count (cells $^{.}10^3$/µL)	0.5-1.4	54	0.54	0.43	0.38	0.27-0.69
CD3+CD8+ %	12-40	54	23.36	24.15	9.82	15.6-30.5
CD4+CD8+ count (cells $^{.}10^3$/µL)	0.25-1	54	0.28	0.20	0.22	0.12-0.36
CD19+ %	5-20	51	12.39	11.50	6.88	8-14.83
CD19+ count (cells $^{.}10^3$/µL)	0.1-0.5	51	0.13	0.10	0.09	0.06-0.20
Natural Killer %	5-20	51	16.06	15.00	9.09	8-20.6
Natural Killer count (cells $^{.}10^3$/µL)	0.5-5	51	0.17	0.14	0.12	0.08-0.20
Immunoglobulin G (mg/dL)	650-1600	19	961.6	933.0	131.3	885-1006
Immunoglobulin A (mg/dL)	40-350	19	230.9	223.0	72.3	178-248
Immunoglobulin M (mg/dL)	50-300	19	103.1	90.0	39.8	72-129
Laboratory data at discharge						
IL6 (pg/mL)	<4.4	114	100.46	8.84	721.15	3.9-21.77
CRP (mg/L)	<10	286	30.75	13.72	45.52	5-37.7
ferritin (ng/mL)	20-250	197	819.80	633	865.41	290-1163
D- dimer (µg/L)	<500	256	3264.93	590.5	34427.29	366-1127
LDH (U/L)	120-246	257	272.76	234	312.86	195-280
days from admission to discharge		129	10.83	10	6.55	7-14
Leucocyte count (cells $^{.}10^3$/µL)	4-12.4	309	7.22	6.38	3.39	4.96-8.28
Neutrophil count (cells $^{.}10^3$/µL)	1.9-8	309	4.93	4.04	3.35	2.92-5.8
Lymphocyte count (cells $^{.}10^3$/µL)	0.9-5	309	1.52	1.43	0.76	1-1.9
Lymphocyte %	19-48	309	23.77	24	11.77	14.8-31.6
CD3+CD4+ %	25-65	13	49.86	54	14.69	49-58.24
CD3+CD8+ %	12-40	13	19.88	20	10.42	10-29.27

CD19 %	5-20	13	16.67	10.86	21.12	7.9-15
Natural Killers %	5-20	13	11.64	11	5.70	9-15

Abbreviations: RASB, renin-angiotensin system blockers; Ref.v, reference values; SD, standard deviation; IQR, interquartile range; IL6, interleukin 6; CRP, C-reactive protein; LDH, lactate dehydrogenase.

Table 2. Risk Factors by severity

	Mild	**Moderate**	**Severe**
Age (p=0.014)			
<30	9 (40.9)	9 (40.9)	4 (18.2)
30-45	26 (40.0)	23 (35.4)	16 (24.6)
45-60	41(26.8)	62 (40.5)	50 (32.7)
60-75	44 (33.3)	57 (43.2)	31 (23.5)
>75	39 (19.3)	90 (44.6)	73 (36.1)
Gender (p<0.001)			
Male	75 (22.0)	141 (41.3)	125 (36.7)
Female	69 (23.8)	129 (44.5)	92 (31.7)
Hypertension (p=0.04)			
No	88 (33.5)	105 (39.9)	70 (26.6)
Yes	69 (23.8)	129 (44.5)	92 (31.7)
RASBª intake (p=0.031)			
No	19(17.1)	47 (42.3)	45 (40.5)
Yes	49(25.7)	86 (45.0)	56 (29.3)
Dyslipidemia (p=0.006)			
No	127(32.8)	155 (40.1)	105 (27.1)
Yes	30(19.1)	74 (47.1)	53 (33.8)
Diabetes (p=0.007)			
No	133 (32.1)	171 (41.3)	110 (26.6)

Yes	2 4(18.6)	58 (45.0)	47 (36.4)
Immunodeficiency			
No	281 (60.9)	373 (80.7)	270 (58.4)
Yes	8 (68.9)	20 (101.4)	11 (29.7)

Abbreviations: RASB, renin-angiotensin system blockers

Table 3. Influence of age and gender on comorbidities

		Age					Gender	
		<30	**30-45**	**45-60**	**60-75**	**>75**	**Male**	**Female**
		n(%)	**n(%)**	**n(%)**	**n(%)**	**n(%)**	**n(%)**	**n(%)**
Hypertension[*]	no	20(7.6)	53(20.2)	95(36.1)	52(19.8)	43(16.3)	149(56.7)	114(43.3)
	yes	1(0.3)	8(2.8)	50(17.2)	76(26.2)	155(53.4)	179(61.7)	111(38.3)
Dyslipidemia[*]	no	21(5.4)	56(14.5)	115(29.7)	78(20.2)	117(30.2)	221(57.1)	166(42.9)
	yes	0(0)	3(1.9)	30(19.1)	48(30.6)	76(48.4)	101(64.3)	56(35.7)
Diabetes[*]	yes	1(0.8)	5(3.9)	18(14)	37(28.7)	68(52.7)	87(67.4)	42(32.6)

[*] all p-values either vs age or gender were <0.001

FIGURES

Figure 1. Severity related changes of laboratory parameters by age

Figure 2. Severity related changes of laboratory parameters by gender

Figure 3. Severity factor interactions

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Age and Laboratory results by severity

	severity p-value	Δa-d p-value	n	mean	median	SD	IQR
Age	.001						
Mild			159	59.11	61.00	16.76	49-70
Moderate			241	64.20	66.00	16.02	55-77
Severe			174	65.43	65.50	15.96	54-79
On admission							
IL6[d] (pg/mL)	.000						
Mild			78	31.40	17.60	40.53	9-40.9
Moderate			97	78.33	43.50	156.04	19.5-87.3
Severe			78	241.40	87.45	597.83	32.6-239.7
CRP[e] (mg/L)	.000	.000					
Mild			132	66.58	44.45	67.92	17.45-88.25
Moderate			228	109.30	93.80	83.51	43.85-148.7
Severe			158	153.19	129.30	108.11	64.5-218.3
ferritin (ng/mL)	.000						
Mild			80	711.39	491.45	881.96	201.65-874
Moderate			132	1004.26	774.00	906.00	381-1504.5
Severe			83	1672.00	1074.00	2413.19	725-1803
D-dimer (ng/mL)	.000						
Mild			121	1088.61	524.00	3669.37	352-800
Moderate			199	1440.46	593.00	3887.70	388-1000
Severe			135	3266.17	981.00	13853.06	470-1587
LDH[f] (U/L)	.000						
Mild			125	252.50	243.00	75.15	201-292
Moderate			204	315.96	293.00	123.64	241.5-372.5
Severe			130	443.58	401.00	276.60	282-524
Leucocyte count (cells*10³/µL)	.000						
Mild			148	6.22	5.70	2.45	4.695-7.005
Moderate			241	7.60	6.15	7.23	4.7-8.82
Severe			173	8.79	8.10	4.69	5.58-10.3
Neutrophil count (cells*10³/µL)	.000						
Mild			148	4.31	3.88	2.20	2.99-5.16
Moderate			241	5.40	4.29	3.77	3.23-7
Severe			173	7.18	6.43	4.12	4.4-8.73
Lymphocyte count (cells*10³/µL)	.000						

			N	Mean	Median	SD	Range
Mild			148	1.30	1.12	0.75	0.86-1.56
Moderate			241	1.14	0.97	0.86	0.73-1.33
Severe			173	1.11	0.90	1.48	0.59-1.24
Lymphocyte %	.000	.000					
Mild			148	22.17	19.75	11.03	14.9-28.6
Moderate			241	18.58	17.10	11.04	9.8-24.5
Severe			173	14.52	11.70	11.09	7.34-18.1
CD3+CD4+ %							
Mild			8	41.31	41.10	6.56	36-47.1
Moderate			32	47.01	47.05	11.14	40.15-53.7
Severe			14	41.39	41.90	10.91	35-52
CD3+CD4+ count (cells*10^3/µL)							
Mild			8	0.74	0.71	0.46	0.32-1.15
Moderate			32	0.54	0.44	0.39	0.26-0.68
Severe			14	0.41	0.33	0.27	0.26-0.46
CD3+CD8+ %							
Mild			8	26.23	27.00	4.26	22.7-28.9
Moderate			32	21.37	19.70	10.58	12.295-30
Severe			14	26.28	28.30	9.60	18.78-34
CD4+CD8+ count (cells*10^3/µL)	.033						
Mild			8	0.45	0.40	0.28	0.20-0.69
Moderate			32	0.24	0.18	0.18	0.13-0.34
Severe			14	0.28	0.25	0.21	0.08-0.47
CD19+ %							
Mild			8	11.50	10.90	3.36	8.95-13
Moderate			32	11.82	10.55	6.22	7.5-15.9
Severe			11	14.70	12.00	10.06	9.2-14.83
CD19+ count (cells*10^3/µL)							
Mild			8	0.19	0.18	0.11	0.09-0.29
Moderate			32	0.13	0.09	0.09	0.06-0.20
Severe			11	0.11	0.10	0.08	0.06-0.12
Natural Killer %							
Mild			8	15.59	13.80	8.96	8.55-23.55
Moderate			32	16.16	15.40	8.34	11.85-19.5
Severe			11	16.09	11.40	11.87	5.9-28.2
Natural Killer count (cells*10^3/µL)							
Mild			8	0.23	0.16	0.15	0.12-0.37
Moderate			32	0.17	0.16	0.12	0.08-0.21
Severe			11	0.11	0.11	0.06	0.06-0.14
IgG (mg/dL)	.048						
Mild			1	1006.00	1006.00	.	1006-1006
Moderate			13	998.31	934.00	133.23	915-1071

			N	Mean	Median	SD	IQR
Severe			5	857.20	862.00	76.43	788-885
IgA (mg/dL)							
Mild			1	248.00	248.00	.	248-248
Moderate			13	234.00	223.00	86.48	175-248
Severe			5	219.40	218.00	28.98	213-230
IgM (mg/dL)	.009						
Mild			1	129.00	129.00	.	129-129
Moderate			13	118.00	121.00	34.88	88-141
Severe			5	59.20	58.00	13.83	50-72

At discharge							
IL6 (pg/mL)	.027						
Mild			55	21.17	11.60	28.51	4.77-23.2
Moderate			49	45.52	7.20	127.31	1.88-12.1
Severe			10	805.81	24.86	2414.69	4.2-67.55
CRP (mg/L)		.000					
Mild			117	28.78	14.70	34.07	6.3-41.8
Moderate			131	30.48	14.00	43.35	4-36
Severe			38	37.76	8.00	75.19	4-26.1
ferritin (ng/mL)		.000					
Mild			78	626.88	388.50	656.13	245-832
Moderate			90	780.99	687.50	611.21	321-1182
Severe			29	1459.12	1123.00	1529.51	713-1840
D-dimer (ng/mL)		.000					
Mild			96	703.70	474.00	927.63	327-752.5
Moderate			122	5526.71	608.50	49845.70	365-1109
Severe			38	2473.89	1309.00	2549.46	797-3912
LDH (U/L)		.000					
Mild			103	237.39	219.00	73.14	192-269
Moderate			115	245.90	228.00	84.11	191-270
Severe			39	445.38	280.00	766.59	235-331
Leucocyte count (cells*10^3/μL)		.000					
Mild			126	6.09	5.78	2.25	4.76-7.12
Moderate			141	7.41	6.88	3.08	5.23-9.17
Severe			42	9.99	9.12	5.16	6.19-12.6
Neutrophil count (cells*10^3/μL)		.000					
Mild			126	3.97	3.57	2.28	2.67-4.46
Moderate			141	5.04	4.40	3.00	3.09-6
Severe			42	7.47	6.50	5.29	3.78-9.6
Lymphocyte count (cells*10^3/μL)	.030	.000					
Mild			126	1.49	1.44	0.62	1.06-1.88
Moderate			141	1.53	1.40	0.86	0.97-1.87
Severe			42	1.56	1.56	0.81	0.8-2.14

Lymphocyte %	.000				
Mild		126	25.60	26.10	9.19	19.5-32.1
Moderate		141	23.15	22.70	12.81	13.7-30.3
Severe		42	20.35	19.35	14.10	8.6-28
CD3+CD4+ %						
Mild		3	49.33	54.00	13.61	34-60
Moderate		10	50.02	53.50	15.70	49-58.24
Severe		0				
CD3+CD8+ %						
Mild		3	20.33	20.00	11.50	9-32
Moderate		10	19.75	20.00	10.74	10-29.27
Severe		0				
CD19 %						
Mild		3	15.00	17.00	6.24	8-20
Moderate		10	17.17	10.68	24.18	7-13
Severe		0				
Natural Killer %						
Mild		3	13.67	15.00	4.16	9-17
Moderate		10	11.03	10.50	6.14	7-15
Severe		0				

Abbreviations: Δa-d, differences between admision and discharge; SD, standard deviation; IQR, interquartile range; IL6, interleukin 6; CRP, C-reactive protein; LDH, lactate dehydrogenase.